Hanx Biopharmaceuticals (Wuhan) Co., Ltd. repurchased 23,700 H-shares on 10 April 2026 via on-exchange transactions, paying an average HK$30.18 per share within a price range of HK$29.50–30.66. The transaction cost totalled HK$0.72 million.

Following the buyback, issued shares excluding treasury stock fell 0.017 % to 136.11 million, while treasury shares rose to 109,800. Total issued shares remained unchanged at 136.22 million.

The purchases were made under the repurchase mandate approved on 12 February 2026, which allows Hanx Biopharmaceuticals to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 109,800 shares, equivalent to 0.0806 % of the issued share base at the mandate date.

Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 10 May 2026. All repurchases were confirmed by the board as compliant with relevant regulations.